19th MEET THE PROFESSOR
Advanced International Breast Cancer Course 2023
(AIBCC 2023)
Palazzo della Salute, Padova
Presentation
Aims
Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
The 19th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.
Addressed to
Scientific Program
Thursday, September 21st
10:00 | Introduction to the Conference Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat |
SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION
Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly
10.30 | Gene expression tools in early-stage HR+/HER2- breast cancer: when and which one? Gaia Griguolo |
11.00 | Biological insights of the immune system in breast cancer Maria Vittoria Dieci |
11.30 | DNA NGS-based biomarkers in advanced breast cancer: how, where and which ones? Mafalda Oliveira |
12.00 | Tackling diversity in HER2-positive breast cancer: biological and clinical implications Tomas Pascual |
12.30 | Discussion |
13.00 | Lunch |
SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS
The changing relationship between locoregional recurrences and long-term outcomes
Chairpersons: Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas
14.00 | Mapping local and regional recurrences Orit Kaidar-person |
14.30 | The surgical perspective Eleftherios Mamounas |
15.00 | Deciphering the EBCTCG meta-analyses Philip Poortmans |
15.30 | Discussion |
Multidisciplinary Tumor Board 1 – Locoregional treatment Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Hesham Ahmed Gaballah Elghazaly |
|
16.00 | Clinical case 1. Skin flap thickness for IBR Rosa Di Micco |
16.15 | Clinical case 2. When to resect/irradiate after systemic therapy for a recurrence Luca Visani |
16.30 | Clinical case 3: Local recurrence after DCIS Eleonora Ferrara |
16.45 | General discussion and concluding comments Jacek Jassem, Hesham Ahmed Gaballah Elghazaly |
17.00 | Adjourn |
17.15 | Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2023 |
17.30 | Lecture of the Awardee |
18.00 | Adjourn |
Friday, September 22nd
SESSION III – EARLY BREAST CANCER
Chairpersons: Alessandra Gennari, Valentina Guarneri
9.00 | New therapeutic strategies in very young women: lights and shadows Angela Toss |
9.20 | Elderly patients: how old is too old in the contemporary scenario Laura Biganzoli |
9.40 | Neoadjuvant approach: rethinking the paradigm? Federica Miglietta |
10.00 | New ESMO Guidelines Sibylle Loibl |
10.20 | Discussion |
10.50 | Coffee break |
Multidisciplinary Tumor Board 2 – Early breast cancer Panelists: Maria Vittoria Dieci, Alessandra Gennari, Valentina Guarneri, Eleftherios Mamounas, Sibylle Loibl, Philip Poortmans |
|
11.15 | Genomic test in premenopausal patients Davide Massa |
11.30 | Adjuvant CDK 4/6 in patients with potential clinical indication but with low genomic risk Michele Bottosso |
11.45 | HER2+ pt1cN0: adjuvant or neoadjuvant? Ottavia Amato |
12.00 | General discussion and concluding comments Alessandra Gennari |
12.30 | Lunch |
SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS
Chairpersons: Giuseppe Curigliano, Pierfranco Conte
13.30 | HR+ disease: is there any preferred treatment sequence at the time of endocrine-resistance? Stephen Johnston |
14.00 | HER2+ disease: from guidelines to a personalized approach based on tumor and patient characteristics Sandra Swain M |
14.30 | Triple negative disease: something more than label indications to dictate treatment sequence? Hope Rugo |
15.00 | Discussion |
Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer Panelists: Pierfranco Conte, Giuseppe Curigliano, Stephen Johnston, Hope Rugo, Sandra Swain |
|
15.30 | Visceral crisis Grazia Vernaci |
16.00 | Leptomeningeal metastases Cristina Falci |
16.15 | General discussion and concluding comments Carlo Alberto Giorgi |
16.30 | Take home messages and adjourn Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans |
Award & Fellowship
Faculty
Honorary President
Directors
Scientific Commitee
Bettina Borisch
Geneve (CH)
Maria Vittoria Dieci
Padova (I)
Hesham Ahmed Gaballah Elghazaly
Cairo (EG)
Jacek Jassem
Gdansk (PL)
Stephen Johnston
London (UK)
Sibylle Loibl
Frankfurt (D)
Eleftherios Mamounas
Orlando (USA)
Miguel Martin
Madrid (E)
Fedro Alessandro Peccatori
Milano (I)
Sandra M. Swain
Washington (USA)
Speakers
Ottavia Amato
Padova (I)
Laura Biganzoli
Prato (I)
Michele Bottosso
Padova (I)
Giuseppe Curigliano
Milano (I)
Rosa Di Micco
Milano (I)
Cristina Falci
Padova (I)
Eleonora Ferrara
Novara (I)
Alessandra Gennari
Novara(I)
Oreste Davide Gentilini
Milano (I)
Carlo Alberto Giorgi
Padova (I)
Gaia Griguolo
Padova (I)
Orit Kaidar-Person
Ramat Gan (IL)
Davide Massa
Padova (I)
Federica Miglietta
Padova (I)
Mafalda Oliveira
Barcellona (E)
Tomàs Pascual
Barcellona (E)
Hope Rugo
San Francisco (USA)
Angela Toss
Modena (I)
Hope Rugo
San Francisco (USA)
Grazia Vernaci
Padova (I)
Luca Visani
Firenze (I)